Interaction and Innovation Areas of the China (Chongqing) Pilot Free Trade Zone Release 17 "Outstanding Practice Cases"

On March 9, a reporter from Chongqing Daily learned from the Chongqing Municipal Commission of Commerce that the Office of the Leading Group for the Work of the China (Chongqing) Pilot Free Trade Zone recently officially issued the Second Batch of Outstanding Practice Cases of the Interaction and Innovation Areas of the China (Chongqing) Pilot Free Trade Zone, with a total of 17 cases selected.

A relevant official from the Chongqing Municipal Commission of Commerce stated that the release of these outstanding cases aims to showcase the achievements in developing the interaction and innovation areas of the China (Chongqing) Pilot Free Trade Zone, promote the replication and wider adoption of innovative practices, and further foster a positive atmosphere of benchmarking, healthy competition, and the pursuit of excellence among interaction and innovation areas. 

The selection process was highly competitive. Following rigorous evaluation and multiple rounds of screening, 17 representative and exemplary cases were ultimately selected across four categories, namely replication and promotion of free trade practices, independent reform and innovation, development of open industries, and regional coordinated linkage. These cases serve as "benchmark models" that demonstrate the vitality of free trade zone and interaction and innovation areas.

For example, the case titled "Exploring a New Full-Chain Service Model for the Biomedicine Industry" in CQETDZ Interaction and Innovation Area addresses key challenges such as the difficulty of industry R&D, gaps in the modernization of industrial governance systems and capabilities, and bottlenecks in the efficient linkage of full-chain industrial factors. Through digital means including the development of AI-powered R&D platforms, industrial internet, industrial brain systems, and navigation agents, the initiative has driven innovative medical-engineering collaboration and reshaped drug regulatory services. It also formulated China's first Healthcare Security Services-General Principles, comprehensively enhancing service capabilities for the biopharmaceutical industry and fostering a more competitive open innovation ecosystem.

Specifically, this model pioneered the world's first AI-powered full-parameter druggability prediction platform for compounds and the world's first AI-powered R&D platform for natural products, improving the efficiency of innovative drug development. It also innovatively established a "Industrial Internet + Intelligent Agent" system for the biomedicine sector to provide one-stop services. In addition, it explored a medical-engineering integration model between medical institutions and biomedicine enterprises to enhance collaborative linkage.

Through this model, the CQETDZ has enabled productivity growth for more than 500 national and international research institutes, universities, new drug R&D enterprises, and manufacturing companies through data value enhancement, platform services, results empowerment, industrial clustering, and an intelligent ecosystem. It has supported multiple enterprises in conducting international intellectual property licensing transactions and accelerated the successful market launch of new drugs developed by several world-renowned pharmaceutical companies. The initiative has empowered innovative development in over a hundred industrial parks nationwide, served more than 50,000 Chinese and international enterprises and government institutions, and reached more than 1.5 million C-end users. Meanwhile, the first Brain and Intelligence Science Center in western China within the CQETDZ has achieved innovative breakthroughs through this initiative, while the brain-inspired industry park has filled the gap in typical application scenarios for brain-computer interface technologies in Chongqing.

Source: Chongqing Daily